Cytology in the time of coronavirus disease (COVID-19): an Italian perspective

Author:

Vigliar Elena,Iaccarino Antonino,Bruzzese Dario,Malapelle UmbertoORCID,Bellevicine Claudio,Troncone GiancarloORCID

Abstract

IntroductionThe coronavirus disease 2019 (COVID-19) is changing the way we practice pathology, including fine needle aspiration (FNA) diagnostics. Although recommendations have been issued to prioritise patients at high oncological risk, postponing those with unsuspicious presentations, real world data have not been reported yet.MethodsThe percentages of the cytological sample types processed at the University of Naples Federico II, during the first 3 weeks of Italian national lockdown were compared with those of the same period in 2019.ResultsDuring the emergency, the percentage of cytology samples reported as malignant increased (p<0.001), reflecting higher percentages of breast (p=0.002) and lymph nodes FNAs (p=0.008), effusions (p<0.001) and urine (p=0.005). Conversely, thyroid FNAs (p<0.001) and Pap smears (p=0.003) were reduced.ConclusionsEven in times of COVID-19 outbreak, cytological examination may be safely carried out in patients at high oncological risk, without the need to be postponed.

Publisher

BMJ

Subject

General Medicine,Pathology and Forensic Medicine

Reference11 articles.

1. Coronavirus Disease 2019 (COVID-19) in Italy

2. Government of Italy . Decree of the President of the Council of ministers 9 March 2020, 2020. Available: https://www.gazzettaufficiale.it/eli/id/2020/03/09/20A01558/sg

3. Centers for Disease Control and Prevention (CDC) . Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19), 2020. Available: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety- guidelines.html

4. World Health Organization . Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV): interim guidance, 2020. Available: https://www.who.int/docs/default-source/coronaviruse/ laboratory-biosafety-novel-coronavirus-version-1-1. pdf?sfvrsn=912a9847_2

5. SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) - Canada.ca, 2020. Available: https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directives-advisories-notifications/novel-coronavirus-january-27.html

Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3